JUL 1 1 2005

Typed or printed name

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduc are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/667,167 **TRANSMITTAL** Filing Date 09/17/2003 First Named Inventor **FORM** Michael A. Munchhof Art Unit 1625 Examiner Name Patricia L. Morris (to be used for all correspondence after initial filing) Attorney Docket Number PC25396A Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC $\overline{ }$ Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Pfizer Inc. Signature Printed name Nicholas J. Sisti Date Reg. No. 54,453 05 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

Examiner: P. Morris

Group Art Unit: 1625

Confirmation No. 8566

IPW IPW

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 7th day of July, 2005.

JUL 1 2005

(Signature of person mailing)

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Munchhof, Michael, J., et al.

APPLICATION NO.: 10/667,167

FILING DATE: September 17, 2003

TITLE: Novel Isothiazole and Isooxazole

Compounds as Transforming Growth Factor

(TGF) Inhibitors

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Supplemental Amendment and Response Under 37 CFR § 1.116

In response to the Office Action dated May 6, 2005, Applicants respectfully request reconsideration of the subject application in view of the following remarks. This response is filed within the shortened statutory period of three months of the mailing date of this Final Action.

Amendments to the claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks / Arguments begin on page 5 of this paper.